comparemela.com

Latest Breaking News On - Repligen company profile - Page 2 : comparemela.com

Repligen (NASDAQ:RGEN) Shares Gap Up to $157 48

Repligen Co. (NASDAQ:RGEN – Get Free Report)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $157.48, but opened at $166.49. Repligen shares last traded at $171.99, with a volume of 139,951 shares changing hands. Analyst Ratings Changes A number of research analysts have weighed in on RGEN […]

LRT Capital Management LLC Purchases 502 Shares of Repligen Co (NASDAQ:RGEN)

LRT Capital Management LLC lifted its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,707 shares of the biotechnology company’s stock after purchasing an additional 502 shares during the quarter. LRT […]

Repligen Co (NASDAQ:RGEN) Receives Consensus Recommendation of Moderate Buy from Analysts

Repligen Co. (NASDAQ:RGEN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target […]

TimesSquare Capital Management LLC Sells 102,636 Shares of Repligen Co (NASDAQ:RGEN)

TimesSquare Capital Management LLC Sells 102,636 Shares of Repligen Co (NASDAQ:RGEN)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Repligen Co (NASDAQ:RGEN) to Post Q1 2024 Earnings of $0 30 Per Share, William Blair Forecasts

Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at William Blair cut their Q1 2024 earnings per share (EPS) estimates for shares of Repligen in a research report issued to clients and investors on Thursday, February 22nd. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.30 per share for […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.